OFFICE OF FISCAL ANALYSIS
Legislative Office Building, Room 5200
Hartford, CT 06106 (860) 240-0200
http://www.cga.ct.gov/ofa
sSB-307
AN ACT CONCERNING MEDICAID COVERAGE OF BIOMARKER
TESTING.
As Amended by Senate "A" (LCO 3931)
Senate Calendar No.: 211
Primary Analyst: LD 4/18/24
Contributing Analyst(s): ES
Reviewer: RW
OFA Fiscal Note
State Impact: None
Municipal Impact: None
Explanation
The bill, which requires Medicaid coverage of biomarker testing for
the purpose of diagnosis, treatment, appropriate management or
ongoing monitoring of a Medicaid enrollee's disease or condition, is not
anticipated to result in a fiscal impact as such testing is currently
covered.
Senate "A" strikes the language in the underlying bill and the
associated fiscal impact and results in the fiscal impact described above.
The Out Years
The annualized ongoing fiscal impact identified above would
continue into the future subject to the conditions on which biomarking
testing is covered.
The preceding Fiscal Impact statement is prepared for the benefit of the members of the General Assembly, solely
for the purposes of information, summarization and explanation and does not represent the intent of the General
Assembly or either chamber thereof for any purpose. In general, fiscal impacts are based upon a variety of
informational sources, including the analyst’s professional knowledge. Whenever applicable, agency data is
consulted as part of the analysis, however final products do not necessarily reflect an assessment from any
specific department.